Enhanced FDA reporting, full IQ/OQ package & incubator monitoring sensor round out Lab21 offerings

Expert life science compliance consulting firm TRESTLE Compliance partners with qordata to leverage TRESTLE's compliance expertise and qordata's compliance management tools to provide life science innovators comprehensive compliance solutions that mitigate risks and maximize effectiveness.

Company will provide the bioscience real estate sector's only online archive of life science properties, as well as industry statistics and resources, national and regional market reports, and strategic networking events.

Nasal Swab Validation for Monkeypox

Recardio Inc., a clinical-stage life science company focusing on regenerative therapies for cardiovascular diseases, announced the completion of its Phase 2, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Study of Dutogliptin in Combination with Filgrastim in Early Recovery Post-Myocardial Infarction.

Brings Deep Biopharma Industry Experience to Support Global Advisory Firm's Mission to Optimize Life Sciences Sector's Clinical Operations & Development Processes

Recardio Inc., a life science company developing regenerative therapies for cardiovascular diseases, announced that its positive results of the interim analysis of Recardio's Phase II clinical trial in AMI were published in the latest release of the European Heart Journal. The current version of the journal relates to the presentation during the 2020 Congress of the European Society of Cardiology.

NYC-Based Startup Demonstrates Versatility of Cell-Culture Technology

Recardio Inc., a life science company developing regenerative therapies for cardiovascular diseases, announced that the results of the interim analysis of Recardio's Phase II clinical trial will be presented at the 2020 Congress of the European Society of Cardiology from August 29 through September 1.

Recardio Inc., a life science company developing regenerative therapies for cardiovascular diseases, announced publication of the outcomes of the Phase 1 clinical trial of its lead candidate dutogliptin. Entitled "Safety, tolerability, pharmacokinetics, and pharmacodynamics of parenterally administered dutogliptin: A prospective dose escalating trial", the article can be accessed here: https://bpspubs.onlinelibrary.wiley.com/doi/full/10.1111/bcp.14208

Solution helps ensure information accuracy, timeliness of submissions and full transparency

It is as vital as ever to understand how to streamline the commercialization of technology being developed within universities and through university partnerships. At 7th Annual Keiretsu Forum Mid-Atlantic Investor Capital Expo, Keith Marmer, Executive Director, Associate Vice President for Technology & Venture Commercialization at the University of Utah, will explore this topic with attending investors.

This week, Keiretsu Forum Mid-Atlantic introduces the next workshop in the Investor Academy series. The group will explore the truths and debunk the myths associated with Life Science Exits.

New AI Platform Accelerates Scientific Research and Drug Discovery, includes over 300 Million Product Listings from 50,000 Vendors

A term sheet is a startup company's most important marketing tool. In this workshop, Keiretsu Forum Mid-Atlantic will explore the most important elements for an investor and startup to consider when negotiating terms.

Keiretsu Forum Mid-Atlantic will take four portfolio companies to the 2019 Angel Capital Association Summit. Local angels hope that one of the four companies snag "Best of Show," securing a "four-peat" for this angel investment group.

Chris Mansur and Ryan Ott, both Azzur Group veterans, assume new appointments following the Group's growth and further diversification.

Keiretsu Forum Mid-Atlantic and CONNECTpreneur partner to improve opportunity and services to entrepreneurs and patient investors in the region.

Carmell Therapeutics was elected as the Stephen M Goodman Most Valued Company at the 6th Annual Keiretsu Forum Mid-Atlantic and South-East Angel Capital Expo. Carmel Therapeutics will accept the award at Pittsburgh Chapter meeting on Friday.

YourEncore & Biocom alliance to help accelerate life science innovation and growth

"Metabesity" names target and serves as a call to action

Suite of services facilitates transition, delivers results, and positions companies for the future

Labscoop's eCommerce Engine will allow J.M. Maris to highlight product quality and increase visibility among next generation researchers.

The latest funding round was led by Maverick Capital Ventures and also included participation from Union Square Ventures, Index Ventures, OATV, Collaborative Fund, YC Continuity Fund, Jose Suarez (CEO of TEDMED), Sam Altman, Steve Case, Paul Buchheit, and others. The company has now raised over $30 million.

The Labscoop application will allow Atlas Antibodies to highlight product quality, reliability and increase accessibility among US, European, and Canadian researchers.

Largest European Event for Biologics Returns to Lisbon from 2-6 November

Molekula strives to bring chemicals on-demand to R&D scientists and engineers by offering 24-48hr fulfillment for growing number of over 6,000 chemicals.

Speakers and Attendees Looking Forward to Networking Opportunities at Upcoming Conference

Evidence-Based Advocacy, International Advocacy Relations Among New Topics to be Addressed

E-learning, Open Payment Lessons, Curriculum Planning Among Topics for Discussion

Regulatory Compliance Enforcement Trends, Corporate Compliance Enforcement Among Discussion Topics